美股异动 | 阿斯利康(AZN.US)盘前涨逾4% Q3核心每股盈利超预期

Core Viewpoint - AstraZeneca reported strong third-quarter results, with total revenue increasing by 12% year-over-year to $15.191 billion, driven by robust sales of key cancer and diabetes drugs [1] Financial Performance - Total revenue for the first nine months grew by 10% year-over-year to $43.236 billion, with core earnings per share at $7.04 [1] - Core earnings per share for the third quarter were $2.38, exceeding market expectations of $2.27 [1] Future Guidance - The company reaffirmed its guidance for high single-digit revenue growth and low double-digit growth in core earnings per share for the full year, aligning with market expectations [1] - AstraZeneca plans to announce a full-year dividend of $3.20 per share for 2025, up from $3.10 last year [1]